James E. Flynn - 11 Aug 2025 SCHEDULE 13G Report for BridgeBio Oncology Therapeutics, Inc. Common Stock

Filing Manager
James E. Flynn
Reporting Manager
Deerfield Management Company, L.P.
Security
BridgeBio Oncology Therapeutics, Inc. Common Stock
Shares outstanding
79,180,648 shares
Disclosed Ownership
4,885,446 shares
Ownership
6.2%
Form type
SCHEDULE 13G
Filing time
18 Aug 2025, 17:59:19 UTC
Date of event
11 Aug 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deerfield Mgmt, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Mgmt V, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Partners, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Private Design Fund V, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Management Company, L.P. 6.2% 4,885,446 0 4,885,446 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
James E. Flynn 6.2% 4,885,446 0 4,885,446 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact